1250 results about "Tumor tissue" patented technology

The invention relates to the technical field of medical image processing, in particular to a multimodal-based digestive tract tumor lesion image segmentation method and segmentation system. The method comprises the following steps: acquiring an alimentary canal tumor lesion image, and extracting an alimentary canal tumor ultrasonic image; evaluating the tumor invasion depth based on the digestive tract tumor ultrasonic image; performing focus three-dimensional visual modeling according to the tumor invasion depth to obtain a digestive tract tumor focus model; extracting a tumor tissue pathological image according to the digestive tract tumor lesion image; performing tumor region segmentation based on the tumor tissue pathological image to obtain digestive tract tumor region data; performing tissue arrangement anomaly detection based on the digestive tract tumor region data to obtain tissue arrangement anomaly data; and calculating a tissue arrangement disorder index according to the tissue arrangement abnormal data and the digestive tract tumor area data. According to the invention, the tumor identification accuracy and the malignant region segmentation precision are improved based on the medical image processing technology.

The invention relates to the technical field of medical image processing and tumor treatment, and provides a tumor image boundary identification method and system fused with a fluorescence boundary, and the method comprises the steps: collecting a tumor dynamic fluorescence image sequence and breathing waveform data through a fluorescence imaging device; performing multi-scale noise suppression processing on the image sequence to generate a preprocessed image without artifacts; extracting fluorescence intensity distribution characteristics through a multi-layer characteristic weighted fusion network and generating an intensity distribution matrix; constructing a motion compensation model according to the breathing waveform data, and correcting the boundary displacement of the intensity distribution matrix; fusing the corrected fluorescence features and the tumor tissue texture features to generate an initial tumor boundary contour; iterative topological optimization is carried out on the initial boundary, and boundary discontinuity is eliminated; and mapping the optimized boundary to a space coordinate system of the laser treatment equipment, generating a boundary mapping model and updating the boundary mapping model in real time. The precision and safety of laser treatment can be improved, and damage to normal tissue is reduced.

Electroporation-based therapies (EBTs) employ high voltage pulsed electric fields (PEFs) to permeabilize tumor tissue, resulting in changes in passive electrical properties detectable using electrical impedance spectroscopy (EIS). Currently, commercial potentiostats for EIS are limited by impedance spectrum acquisition time (˜10 s); this timeframe is much larger than pulse periods used with EBTs (˜1 s). Fourier Analysis SpecTroscopy (FAST) is introduced as a methodology for monitoring tissue inter-burst impedance (diagnostic FAST) and intra-burst impedance (therapeutic FAST) during EBTs. FAST is a rapid-capture (<<1 s) technique which enables monitoring of inter-burst and intra-burst impedance during EBTs in real-time. FAST identified a frequency which delineates thermal effects from electroporation effects in measured impedance. Significance: FAST demonstrates the potential to perform EIS, in addition to intra-burst impedance spectroscopy, using existing pulse generator topologies.

The invention relates to the technical field of biological medicine, and discloses a pharmaceutical composition of paclitaxel dimer prodrug nanoparticles and a traditional Chinese medicine compound and application of the pharmaceutical composition, and the pharmaceutical composition is composed of Qiyuansanlong prescription freeze-dried powder and paclitaxel dimer prodrug nanoparticles; wherein the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) or GSH (glutathione) response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs), and the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) and GSH response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs). According to the pharmaceutical composition disclosed by the invention, a traditional Chinese and western medicine synergistic treatment system is innovatively constructed, and the advantage of multi-dimensional synergistic interaction is shown. Firstly, an NQO1 / GSH double-response type intelligent release system is adopted, and a biomarker highly expressed by tumor tissue can be specifically responded to realize precise drug release, so that the PTX concentration in tumors is improved compared with that of a traditional dosage form, and meanwhile, the drug circulation time is prolonged. Secondly, the active ingredients in the Qiyuansanlong prescription freeze-dried powder can significantly down-regulate the PD-L1 expression level, synergistically enhance CD4 + T and CD8 + T cell infiltration, and form chemical-immune dual killing effects.

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same.Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided.The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.

A neurosurgery system for probing brain tissue of a patient for tumorous tissue. The system including a suction tool, an excitation source, an optical instrument, and a controller. The suction tool including a suction cannula defining a lumen, an optical fiber configured to transmit fluorescence emitted by the brain tissue; and an indicator configured to selectively emit visible light. An excitation source is configured to emit an excitation light having a wavelength to induce the fluorescence in the tumorous tissue. The optical instrument is coupled to the optical fiber. The optical instrument configured to convert the fluorescence emitted by the brain tissue and transmitted by the optical and configured to determine that the brain tissue is tumorous based on the electrical signal and activate the indicator based on the determination.

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

The invention relates to Chinese pulsatilla root and stem exosome-like vesicles as well as a preparation method and application thereof. The preparation method comprises the following steps: juicing Chinese pulsatilla roots, filtering, and collecting filtrate; and centrifuging the filtrate, collecting the precipitate, re-suspending, and filtering to obtain a solution containing the exosome-like vesicles of the Chinese pulsatilla roots. Compared with the prior art, the Chinese pulsatilla root and stem exosome-like vesicles extracted by the method can inhibit malignant progression, including proliferation and migration, of lung cancer, and cell uptake and animal living imaging prove that the Chinese pulsatilla root and stem exosome-like vesicles can be taken by cells and can be enriched in tumor tissues at the same time.

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The invention relates to a computer-implemented method for assessing a risk of breast cancer recurrence, to a computer program having instructions which when executed by a computing device or system cause the computer device or system to perform the method as well as to a data-processing system comprising means for carrying out the method for assessing a risk of breast cancer recurrence. The method of the invention is for example performed by whole slide image (WSI) processing, wherein the risk of breast cancer recurrence is assessed from a WSI of a tumor tissue.

The invention discloses an engineered autologous tumor tissue scaffold and application thereof, and the engineered autologous tumor tissue scaffold is prepared by performing specific treatment on autologous tumor tissue to induce immunogenic cell death of the tumor tissue, and then sequentially performing freezing and drying steps; the engineered autologous tumor tissue scaffold can be used for loading dendritic cells and constructing personalized tumor vaccines. According to the stent, autologous tumor tissue is adopted, so that a specific and comprehensive tumor antigen pedigree is reserved, and multi-epitope immunostimulation is provided; and meanwhile, excellent biocompatibility is ensured, the immunological rejection risk is reduced, and relatively high safety is ensured.

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

The invention provides a tumor living body sampling device, and relates to the field of biological sampling, the tumor living body sampling device comprises: a sampler main body, the sampler main body is a pistol-shaped structure; the inner sampling needle is coaxially and rotatably connected to the inner side of the reversing seat, the inner sampling needle is rotatably connected to the inner side of the sampling outer cylinder, the right cross sections of the sampling outer cylinder and the inner sampling needle are of arch-shaped structures, and the right end parts of the sampling outer cylinder and the inner sampling needle are of needle-shaped spine structures; hollow sampling openings are formed in arch-shaped parts on the right sides of the sampling outer cylinder and the inner sampling needle; the sampling transmission assembly is arranged in the sampler main body, and the sampling operation block drives the sampling outer cylinder and the inner sampling needle to rotate reversely at the same time through the sampling transmission assembly. The tumor tissue is rapidly and completely cut off, tearing damage is avoided, samples are isolated from the tissue, the samples are prevented from being mixed, and the problems that in the existing sampling process, the tissue is difficult to effectively cut off, tissue tearing is easily caused, and tissue samples are not pure are solved.

The invention relates to the technical field of medical image processing, and discloses a neurovascular tumor recognition method and system based on multi-modal image fusion, and the system comprises a multi-dimensional collection module and an intelligent recognition module. According to the neural vascular tumor identification method and system based on multi-modal image fusion, PET / CT images and MRI images of a tumor part are obtained through a multi-dimensional acquisition module and are classified to form an image set, and an intelligent identification module carries out gray scale range standardization processing on the images of different modalities according to the same time point; according to the method, the difference between images collected by different devices or time points is eliminated, the images are registered and aligned to a unified three-dimensional coordinate system, the visual fusion registration capacity is high, and an intelligent recognition module analyzes the horizontal diameter and the vertical diameter of tumor tissue and the growth state of the tumor tissue according to the three-dimensional coordinate system, generates a tumor data set and a compression index and displays the tumor data set and the compression index. The compression degree of the tumor tissue on the blood vessel wall is evaluated, corresponding treatment suggestions are output, and the intelligent recognition and diagnosis effect is good.

The invention provides a dual-targeting carrier material, a preparation method thereof and a preparation method of oleanolic acid nanoparticles wrapped by the dual-targeting carrier material, and belongs to the technical field of medicines. The oleanolic acid targeting nanoparticles are prepared by taking a dual-targeting high-molecular copolymer as a carrier material and adopting an emulsification-solvent evaporation method, so that the oleanolic acid can be protected from being quickly degraded, and the in-vivo circulation time of the oleanolic acid can be prolonged. Meanwhile, targeted delivery of oleanolic acid is realized through a targeted group, the concentration of the drug in tumor tissues is improved, and toxic and side effects on normal tissues are reduced. An MTT method is adopted, the inhibition effect of the oleanolic acid nanoparticles on cell growth is researched, and the result shows that the oleanolic acid targeting nanoparticles have a stronger effect of inhibiting tumor cell proliferation compared with an oleanolic acid raw material medicine.

The invention provides application of TRMT61A and its inhibitor tetramethylthiuram disulfide in tumor immunotherapy, and relates to the technical field of biological medicine, clinical research proves that RNA m1A methyltransferase TRMT61A is highly expressed in tumor tissues and is related to poor prognosis of tumor patients, and can be used as one of tumor therapy targets. Meanwhile, high expression of the TRMT61A is related to poor prognosis of a tumor patient receiving anti-PD-1 immunotherapy, and after anti-PD-1 antibody immunotherapy is carried out on the patient with low TRMT61A expression level in the tumor of the patient, pathological complete relief is easier. Tetramethylthiuram disulfide inhibits TRMT61A, inhibits m1A modification regulation of TRMT61A on PD-L1 mRNA, increases PD-L1 protein expression, and is combined with a PD-1 antibody drug to significantly enhance the immunotherapy effect of the anti-PD-1 immune checkpoint drug in treating malignant tumors.

The invention provides an aza-BODIPY molecule with NIR-II fluorescence emission and I-type photodynamic activity and a preparation method thereof. The aza-BODIPY molecule has good light absorption in a near-infrared (NIR) region, the emission peak of the aza-BODIPY molecule is prolonged to a near-infrared second region (NIR-II), and the aza-BODIPY molecule shows an ultrahigh NIR-II fluorescence quantum yield of 13%. Meanwhile, the photosensitizer prepared by adopting aza-BODIPY molecules can effectively generate I-type active oxygen species, namely superoxide anion free radicals, under the excitation of 808nm laser. On the basis, high-resolution tumor fluorescence imaging can be realized by utilizing NIR-II fluorescence of the aza-fluorine boron fluorescent sensitizer, and the aza-fluorine boron fluorescent sensitizer is used for accurate and efficient NIR-II fluorescence imaging mediated I-type photodynamic therapy of deep tumor tissues.

The invention relates to the technical field of biopsy puncture, and discloses a tumor biopsy puncture device for biopsy sampling, the tumor biopsy puncture device comprises an outer needle assembly and an inner needle assembly, the outer needle assembly comprises a needle base and an outer needle tube fixed with the needle base, the inner needle assembly comprises a needle cylinder and an inner needle core slidably arranged in the needle cylinder, a needle cavity is arranged at the needle tip end of the inner needle core, and the needle cavity is communicated with the needle base. An ejection mechanism is arranged in the needle cylinder, the ejection mechanism is used for triggering the inner needle core to eject outwards in the length direction of the outer needle tube, and the ejection mechanism comprises a connecting part fixed to the inner needle core, a locking piece arranged on the connecting part and used for limiting the position of the inner needle core and a pull rod fixed to the connecting part and capable of penetrating out of the needle cylinder in a sliding mode. According to the tumor biopsy puncture equipment for biopsy sampling, by arranging the ejection mechanism, compared with an existing manual operation mode, the ejection force of the inner needle core is adjusted by changing the stretching or compression degree of the elastic component, and the cutting requirements of tumor tissues of different textures can be met.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses a Claudin18.2-targeting nano antibody and application thereof, and belongs to the technical field of molecular biology. Aiming at the unique advantages of a nano antibody in the prior art, the invention provides a nano antibody targeting Claudin18.2, the amino acid sequence of the targeting nano antibody is shown as SEQ ID NO.1, and the nano antibody has relatively strong affinity with Claudin18.2 positive cells 293T-Claudin18.2, and can be combined with Claudin18.2 protein expressed on the surfaces of the cells. The targeted Claudin18.2 nano antibody provided by the invention can be prepared through in-vitro engineering bacterium mass expression, can be applied to preparation of protein detection antibodies or therapeutic antibodies, can be used for in-vivo and in-vitro detection of tumor tissues expressed by Claudin18.2, and has important commercial value in clinical disease diagnosis and treatment.

The invention discloses a multi-modal tumor identification method based on a frequency domain attention mechanism. The method comprises the following steps: S1, acquiring multi-frequency bioelectrical impedance signals of tumor tissues and normal tissues and corresponding medical tumor pathological images; s2, extracting a frequency-time feature of the electrical impedance signal and a spatial feature of the pathological image through a multi-modal feature coding module, and generating a multi-modal fusion feature; s3, converting the multi-modal fusion features into frequency domain representation, performing weighted enhancement on the multi-modal fusion features through a frequency domain attention module, and outputting the features; and S4, fusing the features output by the frequency domain attention module and the superficial layer features in the coding stage through jump connection to obtain enhanced features, inputting the enhanced features into a decoding network, and outputting a tumor classification result. According to the method, the bioelectrical impedance signal and the multi-modal information of the pathological image are fused, and a frequency domain attention mechanism is introduced to effectively improve the expression ability of key frequency characteristics.

The invention relates to the technical field of nano-drug presentation systems, in particular to a TCR (T cell receptor) nano-vesicle antibody with both T cell redirection and immunosuppression reversal as well as a preparation method and application of the TCR nano-vesicle antibody. The TCR nano-vesicle antibody comprises a vesicle formed by a liposome and a cell membrane; tCR protein, a PD-1 antibody and a CD3 antibody are loaded on the vesicles. The nano vesicle antibody has the functions of T cell redirection and immunosuppression reversion; the difficulty of low stability of the soluble TCR is overcome; the polypeptide can be rapidly enriched in tumor tissues through tumor specificity TCR, and CD8 + T cells infiltrated by tumors are directly activated through an anti-CD3 antibody; depletion of T cells can be reversed through the PD-1 antibody on the surface, and the effector function of tumor infiltration CD8 + T cells is improved. The technical scheme can solve the technical problems that the TCR stability is not ideal and the immunosuppression state of the tumor microenvironment is difficult to overcome, and has ideal application and popularization prospects.

The invention belongs to the field of biological medicine, and relates to an engineered cell membrane nano-vesicle as well as a preparation method and application thereof. The invention provides application of normal fibroblasts in preparation of drugs for treating tumors or tumor diagnostic reagents or nano drug delivery systems or engineered vesicles. The vesicles prepared from the normal fibroblasts have high specificity and capability of rapidly targeting multiple types of tumor tissues, can realize tumor targeted diagnosis imaging or drug delivery, greatly reduce accumulation in normal organs and non-targeted tissues, maximally weaken toxic and side effects of the vesicles in vivo, and have good application prospects. And the safety and the effectiveness are greatly improved.

The invention discloses a novel nucleic acid delivery system based on phosphatidylmitoxantrone as well as a preparation method and application of the novel nucleic acid delivery system based on phosphatidylmitoxantrone, and phosphatidylmitoxantrone (PMA) is used as a novel cationic lipid to construct a novel lipidosome nano nucleic acid delivery system by utilizing the enzymatic response release property and ionizable cationic phospholipid characteristics of phosphatidylmitoxantrone (PMA). PMA not only can be used as a novel cationic lipid entrapped nucleic acid, but also can be used as an auxiliary lipid component to promote nucleic acid delivery, so that the synergistic anti-tumor effect of nucleic acid and mitoxantrone is realized. The system can respond to high expression of phospholipase D (PLD) in tumor tissues, promote hydrolysis of PMA and release chemotherapeutic drug mitoxantrone, dual functions of nucleic acid delivery and drug release are achieved, the purpose of double-target inhibition of tumor growth is achieved, and a new strategy is provided for cancer treatment.

The invention relates to the field of biomedical treatment, and particularly discloses application of CD146 in diagnosis and treatment of rhabdomyosarcoma, and the CD146 is specifically and highly expressed in tumor tissues of the rhabdomyosarcoma. The invention provides application of a biomarker for diagnosing rhabdomyosarcoma or / and a detection reagent thereof in preparation of a product for diagnosing rhabdomyosarcoma. Meanwhile, experiments prove that the CD146-targeted chimeric antigen receptor T cell has a relatively strong tumor cell killing effect and can effectively remove CD146 positive tumor cells. The CD146 biomarker provided by the invention provides a new target and theoretical basis for early diagnosis and individualized treatment of rhabdomyosarcoma, and has important clinical application value.

The invention discloses a high-specificity minimal residual disease (MRD) monitoring method and system based on circulating tumor DNA (ctDNA). The method comprises the following steps: receiving tumor tissue sequencing data of an UTUC patient, and generating a double-Panel target list containing personalized and fixed Panel; respectively extracting plasma cfDNA and leukocyte gDNA; performing vacuum concentration, hybrid capture and sequencing on the cfDNA library by using the double Panel lists, and performing deep sequencing on the leukocyte gDNA; constructing an individualized clonal hematopoietic mutation filtering database; actively filtering and rejecting clonal hematopoietic background mutation by utilizing a filtering database; and calculating an MRD load score based on the filtered tumor-derived mutation and outputting a report. The system comprises corresponding modules which are used for automatically executing the process. According to the invention, through cooperation of four major technologies of double-Panel design, process optimization, UMI error correction and active clonal hematopoietic filtration, MRD monitoring with extremely high sensitivity and specificity on UTUC is realized, false positive is significantly reduced, and the kit has drug resistance early warning potential.

The invention relates to the technical field of image recognition, in particular to an intraoperative robot image analysis system for renal tumor resection, which is characterized in that ultrasonic images in renal tumor resection are acquired, part of the ultrasonic images form a training set, and the ultrasonic images are equally divided into a plurality of ultrasonic blocks, each ultrasonic block corresponds to one ultrasonic echo signal, energy of the ultrasonic echo signals under different frequency components is obtained, so that the suppression amount of the ultrasonic echo signals is determined to screen out high-suppression-amount ultrasonic blocks, tumor tissue heterogeneity of the high-suppression-amount ultrasonic blocks is determined to obtain up-sampling weights of pixel points in an ultrasonic image, and the up-sampling weights of the pixel points in the ultrasonic image are obtained. Therefore, the training set is trained, and a trained semantic segmentation network model is obtained and is used for segmenting a kidney tumor area in the ultrasonic image. According to the method, the accuracy of kidney tumor area identification is improved through self-adaptive upsampling weight, so that the kidney tumor resection effect is guaranteed.

The invention relates to the technical field of boron neutron capture therapy, in particular to a dose verification device for boron neutron capture therapy. The objective of the invention is to solve the technical problem that dose distribution of tumor tissues and surrounding thereof cannot be accurately measured. To this end, the dose verification device of the present application comprises: a box; the die body assemblies move in the incident direction of the neutron beam and are arranged in a stacked mode; the die body insertion plate comprises a tumor tissue simulation positioning area containing boron-10 with a first concentration and / or a normal tissue simulation positioning area containing boron-10 with a second concentration, and the first concentration is greater than the second concentration; the dose detection module is used for detecting distribution data of secondary particles generated after the boron-10 and neutrons are subjected to nuclear reaction; and the data processing module is used for acquiring the distribution data and determining the dose distribution in the die body assembly according to the distribution data. According to the application, the difference of the boron-10 concentration of the tumor tissue and the normal tissue can be better simulated, and the dose distribution of the tumor tissue and the surrounding thereof can be more accurately measured.

The invention discloses a manganese-enriched albumin boron-containing nano preparation as well as a preparation method and application thereof, and belongs to the field of medicines and nano biological materials. According to the manganese-enriched albumin boron-containing nano preparation, albumin serves as a core carrier, phenylboronic acid derivatives are loaded through covalent or electrostatic interaction, then a manganese oxide layer is deposited on the surface in situ, and the prepared manganese-enriched albumin boron-containing nano preparation can remarkably increase the boron accumulation amount in tumor tissue; local and systemic immune response of tumors is promoted through the immune activation effect of manganese ions, so that the treatment effect of boron neutron capture therapy (BNCT) is remarkably improved. According to the invention, a phenylboronic acid derivative with tumor targeting is compounded with albumin, and manganese oxide is deposited in situ on the surface of the phenylboronic acid derivative, so that a multifunctional nano preparation with high boron delivery efficiency, immunological enhancement and magnetic resonance imaging functions is formed.

The invention belongs to the technical field of biological medicines, and particularly discloses a bionic nano-vesicle for regulating and controlling neutrophil phenotype in combination with ultrasound, and a preparation method and application of the bionic nano-vesicle. The bionic nano-vesicle provided by the invention can be broken under the action of high-concentration glutathione existing in a tumor tissue microenvironment to release the sound-sensitive agent and functional siRNA, and under the action of US irradiation, the sound-sensitive agent is activated to generate a large amount of ROS, promote tumor cell DNA breakage, generate a large amount of double-stranded DNA, activate APC and promote IFN-beta release, so that the tumor tissue microenvironment is inhibited. The released functional siRNA can promote the N2-type neutrophile granulocyte to become N1-type neutrophile granulocyte, and the released functional siRNA can prevent the N1-type neutrophile granulocyte from being reversed to the N2-type neutrophile granulocyte again, so that the regulation and control on the phenotype of the neutrophile granulocyte are realized; under catalysis of CAT rich in the thylakoid membrane, H2O2 overexpressed by tumor tissue is decomposed into oxygen, the tumor hypoxia microenvironment can be relieved, and the tumor treatment effect can be improved.